Q2 FY25 Financial Performance - Solventum's total sales reached $2161 million, with a reported year-over-year increase of 3.9% and an organic growth of 2.8%[12] - The company's GAAP operating margin was 9.9%, while the non-GAAP operating margin was significantly higher at 21.9%[13] - GAAP EPS stood at $0.51, and non-GAAP EPS was $1.69[13] - Cash from operations amounted to $169 million, while free cash flow was $59 million[13] Segment Performance - MedSurg segment sales were $1218 million, showing a reported increase of 4.8% and an organic growth of 3.9%[12, 15] - Dental Solutions segment achieved $338 million in sales, with a reported growth of 2.3% and an organic growth of 0.7%[12, 19] - Health Information Systems segment reported sales of $339 million, reflecting a 3.4% increase, with organic growth at 3.2%[12, 23] - Purification & Filtration segment's sales were $252 million, with a reported increase of 5.4% and an organic growth of 3.1%[12, 26] FY2025 Guidance - The company raised its organic sales growth guidance to a range of 2.5% to 3.5%, excluding an approximate 50bps impact from SKU exits[29] - Adjusted EPS guidance was increased to $5.80 - $5.95[30]

Financial Performance - Solventum's Q1 FY25 net sales reached $2.1 billion, with organic sales growth of 4.3%[9] - The adjusted operating margin was 19.7%[9] - Adjusted EPS stood at $1.34[9] - Free cash flow was negative $80 million[14] Segment Performance - Dental Solutions reported net sales of $1.157 billion, with organic growth of 6.0%[11] - Health Information Systems achieved net sales of $329 million, with organic growth of 3.9%[11] - Purification & Filtration reported net sales of $242 million, with organic growth of 2.2%[11] FY25 Guidance - Solventum increased its organic sales growth outlook by 50bps to a range of +1.5% to +2.5%[9] - The company is maintaining its adjusted EPS range of $5.45 to $5.65[9] - The free cash flow range is maintained at $450 million to $550 million[9]